NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

RMD

Resmed Inc

Jul 15 • 04:00PM ET

252.01

Dollar change -2.10
Percentage change -0.83	%

Healthcare • Medical Instruments & Supplies • USA • NYSE

Peers: EW BAX BDX ZBH VNT IART TFX COO HSIC XRAY

| Held by: VTI VOO VO SPY IVV VUG VOT XLV VIG IHI

Scroll to Statements

Index	S&P 500	P/E	28.29	EPS (ttm)	8.91	Insider Own	0.70%	Shs Outstand	146.87M	Perf Week	-1.78%
Market Cap	36.95B	Forward P/E	23.76	EPS next Y	10.61	Insider Trans	-8.20%	Shs Float	145.60M	Perf Month	-0.08%
Enterprise Value	36.86B	PEG	1.92	EPS next Q	2.48	Inst Own	66.09%	Short Float	6.96%	Perf Quarter	17.77%
Income	1.31B	P/S	7.36	EPS this Y	22.98%	Inst Trans	3.80%	Short Ratio	11.15	Perf Half Y	7.78%
Sales	5.02B	P/B	6.67	EPS next Y	11.71%	ROA	18.26%	Short Interest	10.13M	Perf YTD	10.20%
Book/sh	37.76	P/C	39.62	EPS next 5Y	14.77%	ROE	25.81%	52W High	263.05 -4.20%	Perf Year	26.14%
Cash/sh	6.36	P/FCF	23.55	EPS past 3/5Y	28.78% 19.83%	ROIC	20.69%	52W Low	196.43 28.30%	Perf 3Y	15.78%
Dividend Est.	2.21 (0.88%)	EV/EBITDA	20.16	Sales past 3/5Y	13.59% 12.44%	Gross Margin	57.87%	Volatility	2.10% 1.66%	Perf 5Y	30.76%
Dividend TTM	2.12 (0.84%)	EV/Sales	7.34	EPS Y/Y TTM	37.23%	Oper. Margin	32.10%	ATR (14)	4.45	Perf 10Y	345.01%
Dividend Ex-Date	May 08, 2025	Quick Ratio	2.49	Sales Y/Y TTM	9.54%	Profit Margin	26.15%	RSI (14)	47.32	Recom	1.86
Dividend Gr. 3/5Y	7.17% 5.34%	Current Ratio	3.41	EPS Q/Q	21.67%	SMA20	-1.19%	Beta	0.77	Target Price	277.42
Payout	27.75%	Debt/Eq	0.15	Sales Q/Q	7.92%	SMA50	0.69%	Rel Volume	1.11	Prev Close	254.11
Employees	9980	LT Debt/Eq	0.14	Earnings	Jul 31 AMC	SMA200	5.60%	Avg Volume	908.07K	Price	252.01
IPO	Jun 02, 1995	Option/Short	Yes / Yes	EPS/Sales Surpr.	-0.34% 0.28%	Trades		Volume	1,009,545	Change	-0.83%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-15-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$294
Mar-19-25	Initiated	Morgan Stanley	Overweight	$280
Mar-19-25	Initiated	Morgan Stanley	Overweight
Jan-16-25	Initiated	Goldman	Buy
Jan-10-25	Initiated	Piper Sandler	Neutral	$252
Dec-13-24	Initiated	Stifel	Hold	$250
Sep-24-24	Initiated	Robert W. Baird	Outperform	$280
Sep-18-24	Downgrade	Wolfe Research	Peer Perform → Underperform	$180
Sep-04-24	Downgrade	Needham	Buy → Hold
Jun-25-24	Downgrade	Oppenheimer	Outperform → Perform
Jun-24-24	Downgrade	Citigroup	Buy → Neutral
Feb-06-24	Resumed	KeyBanc Capital Markets	Overweight	$227
Oct-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$180 → $169
Oct-12-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$273 → $202
Oct-09-23	Upgrade	JP Morgan	Neutral → Overweight	$210 → $170
Sep-29-23	Downgrade	Wolfe Research	Outperform → Peer Perform
Sep-06-23	Upgrade	Needham	Hold → Buy	$180
Sep-05-23	Downgrade	UBS	Buy → Neutral	$265 → $170
Aug-01-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$262 → $284
May-23-23	Initiated	UBS	Buy	$290

Show Previous Ratings

Jul-15-25 12:04AM	2 Reasons to Watch RMD and 1 to Stay Cautious (StockStory)
Jul-09-25 02:33PM	Semler Scientific Stock Gets Relative Strength Rating Upgrade (Investor's Business Daily)
12:35AM	2 S&P 500 Stocks with Promising Prospects and 1 to Steer Clear Of (StockStory)
Jul-01-25 04:05PM	Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025 (GlobeNewswire)
Jun-30-25 09:45AM	Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio (Zacks)
04:40AM	Loading…
Jun-26-25 04:40AM	Zacks.com featured highlights Sprouts Farmers Market, Adobe, GE Aerospace and ResMed (Zacks)
Jun-25-25 12:00PM	All You Need to Know About ResMed (RMD) Rating Upgrade to Buy (Zacks)
08:57AM	Scoop Up These 4 GARP Stocks to Receive Handsome Returns (Zacks)
Jun-24-25 07:33PM	Analyst Report: ResMed Inc. (Morningstar Research)
Jun-18-25 08:27AM	ResMed's Q1 Earnings Call: Our Top 5 Analyst Questions (StockStory)
Jun-10-25 07:00PM	ResMed: A Mixed Bag for Investors Amid Rising Competition (Motley Fool)
Jun-06-25 11:31AM	Phibro (PAHC) Up 7.4% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-04-25 09:45AM	ResMed (RMD) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
Jun-02-25 12:35AM	2 Healthcare Stocks to Keep an Eye On and 1 to Turn Down (StockStory)
May-30-25 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
11:30AM	Loading…
May-23-25 11:30AM	ResMed (RMD) Up 4% Since Last Earnings Report: Can It Continue? (Zacks)
06:52AM	Is it Worth Retaining ResMed Stock in Your Portfolio Now? (Zacks)
May-21-25 10:10AM	Morgan Stanley sees modest earnings impact to ResMed from Apnimed (TipRanks)
May-19-25 09:45AM	Here's Why ResMed (RMD) is a Strong Growth Stock (Zacks)
May-18-25 04:20AM	3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term (Motley Fool)
May-15-25 09:00AM	Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025 (GlobeNewswire)
May-06-25 12:31AM	3 Profitable Stocks to Consider Right Now (StockStory)
May-03-25 10:39PM	Top 50 High-Quality Dividend Stocks For May 2025 (Seeking Alpha)
01:26AM	Dividend Champion, Contender, And Challenger Highlights: Week Of May 4 (Seeking Alpha)
May-02-25 11:21AM	Top 15 High-Growth Dividend Stocks To Consider For May 2025 (Seeking Alpha)
06:50AM	Resmed acquires independent diagnostic testing facility VirtuOx (Medical Device Network)
06:00AM	Intuitive wins new FDA nod for single port robot; Resmed buys diagnostic facility (MedTech Dive)
May-01-25 09:45AM	Why ResMed (RMD) is a Top Growth Stock for the Long-Term (Zacks)
09:00AM	Resmed Acquires VirtuOx (GlobeNewswire)
Apr-30-25 04:03PM	Resmed Inc (RMD): Jim Cramer Says "Remarkable Stock" - Did GLP-1 Drugs Just Hand It a Lifeline? (Insider Monkey)
06:09PM	Loading…
Apr-26-25 06:09PM	RMD Q1 Earnings Call: Margin Expansion and Demand Generation Initiatives Define Quarter (StockStory)
Apr-25-25 12:00PM	MMSI Stock Declines Despite Q1 Earnings Beating Estimates, Margins Up (Zacks)
09:50AM	ResMed (RMD) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
07:10AM	Buy These 5 Low-Leverage Stocks to Counter Market Volatility (Zacks)
Apr-24-25 08:21AM	Q3 2025 Resmed Inc Earnings Call (Thomson Reuters StreetEvents) +10.10%
08:07AM	Analyst Report: ResMed Inc. (Morningstar Research)
07:24AM	ResMed Q3 Earnings and Revenues Beat, Stock Up in After-Market (Zacks)
05:12AM	ResMed: Cornering The Market In Sleep Solutions (Seeking Alpha)
03:06AM	ResMed Inc (RMD) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Apr-23-25 07:16PM	ResMed Inc. (RMD) Q3 2025 Earnings Call Transcript (Seeking Alpha)
06:00PM	Here's What Key Metrics Tell Us About ResMed (RMD) Q3 Earnings (Zacks)
05:15PM	ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates (Zacks)
04:23PM	ResMed's (NYSE:RMD) Q1 Earnings Results: Revenue In Line With Expectations (StockStory)
04:19PM	ResMed: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025 (GlobeNewswire)
03:40AM	Magnificent 7 Earnings Out This Week Will Shed Light On Big Tech's Tariff Concerns (Seeking Alpha)
Apr-22-25 08:02AM	Earnings To Watch: ResMed (RMD) Reports Q1 Results Tomorrow (StockStory)
Apr-21-25 05:00PM	Resmed Names Salli Schwartz as Chief Investor Relations Officer (GlobeNewswire)
10:00AM	Earnings Preview: InMode (INMD) Q1 Earnings Expected to Decline (Zacks)
Apr-17-25 09:15AM	What Analyst Projections for Key Metrics Reveal About ResMed (RMD) Q3 Earnings (Zacks)
Apr-16-25 10:00AM	ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Apr-15-25 09:45AM	Here's Why ResMed (RMD) is a Strong Growth Stock (Zacks)
Apr-14-25 03:00PM	Tap Into the Silver Economy Boom With These Aging Demographics Stocks (Zacks)
Apr-09-25 08:19AM	Analyst Report: ResMed Inc. (Morningstar Research) +5.82%
Apr-08-25 08:39AM	Strength Seen in ResMed (RMD): Can Its 3.8% Jump Turn into More Strength? (Zacks)
Apr-04-25 08:06AM	RMD Stock Benefits From the Launch of NightOwl Across US (Zacks)
Apr-03-25 11:28PM	Top 50 High-Quality Dividend Growth Stocks For April 2025 (Seeking Alpha)
09:41AM	ResMed Inc. (RMD): A Bull Case Theory (Insider Monkey)
09:00AM	Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl , Now Available Across the US (GlobeNewswire)
Apr-02-25 05:35PM	Resmed Inc. (RMD): Jim Cramer Says He Likes This Sleep Apnea Treatment Stock (Insider Monkey)
04:05PM	Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025 (GlobeNewswire)
02:12AM	My Top 15 High-Growth Dividend Stocks For April 2025 (Seeking Alpha)
Mar-28-25 07:04AM	Morgan Stanley Sees Near-Term Rally Ahead Here Are 2 Stocks to Bet on It (TipRanks)
06:25AM	abrdn Australia Equity Fund Commentary For The Quarter Ended January 31, 2025 (Seeking Alpha)
Mar-26-25 10:37AM	Jim Cramer On ResMed Inc. (RMD) - "I'm With Mick! ResMed's Doing Quite Well" (InsiderMonkey)
Mar-24-25 01:00PM	Highly Rated Low Volatility Stocks And ETFs For Today's Market (SeekingAlpha)
Mar-21-25 08:11PM	Lightning Round: Stay away from aluminum, says Jim Cramer (CNBC TV)
Mar-20-25 10:15AM	ResMed initiated with an Overweight at Morgan Stanley (TipRanks)
09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
Mar-19-25 08:00AM	New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer (GlobeNewswire)
Mar-17-25 09:45AM	Why ResMed (RMD) is a Top Growth Stock for the Long-Term (Zacks)
Mar-11-25 09:00AM	Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution (GlobeNewswire)
05:07AM	Patient Monitoring Stocks Q4 Results: Benchmarking ResMed (NYSE:RMD) (StockStory)
Mar-10-25 03:00AM	ResMed Among Top Stocks For Recent And Long-Term Profit Growth (Investor's Business Daily)
Mar-04-25 04:03AM	2 Reasons to Like RMD and 1 to Stay Skeptical (StockStory)
Feb-26-25 09:45AM	Here's Why ResMed (RMD) is a Strong Growth Stock (Zacks)
03:00AM	ResMed's Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep (GlobeNewswire)
Feb-20-25 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook ResMed (RMD) (Zacks)
Feb-19-25 08:11AM	Insulet Earnings: What To Look For From PODD (StockStory)
08:01AM	iRhythm (IRTC) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Feb-14-25 09:55AM	Here's Why ResMed (RMD) Could be Great Choice for a Bottom Fisher (Zacks)
Feb-12-25 08:07AM	DexCom (DXCM) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Feb-11-25 03:00AM	ResMed Getting Close To Elite Stock Group Entry (Investor's Business Daily)
03:00AM	ResMed Close To Joining Very Elite Stock Group (Investor's Business Daily)
Feb-10-25 09:45AM	Why ResMed (RMD) is a Top Growth Stock for the Long-Term (Zacks)
Feb-05-25 07:09AM	Analyst Report: ResMed Inc. (Morningstar Research)
Feb-04-25 12:45PM	Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
09:15AM	Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board (GlobeNewswire)
Feb-03-25 09:50AM	Here's Why ResMed (RMD) is a Strong Momentum Stock (Zacks)
Jan-31-25 07:50PM	Analyst Report: ResMed Inc. (Morningstar Research) -8.33%
04:10PM	ResMed Tumbles As Organic Sales Growth Steps Down. Will These 'Mega Trends' Save It? (Investor's Business Daily)
03:32PM	ResMed (NYSE:RMD) Posts Better-Than-Expected Sales In Q4 But Stock Drops (StockStory)
09:15AM	ResMed Inc. (RMD) Hits Fresh High: Is There Still Room to Run? (Zacks)
08:55AM	Q2 2025 Resmed Inc Earnings Call (Thomson Reuters StreetEvents)
08:44AM	Health Care Roundup: Market Talk (The Wall Street Journal)
02:40AM	ResMed Inc (RMD) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Jan-30-25 10:32PM	Analyst Report: ResMed Inc. (Morningstar Research)
06:30PM	Compared to Estimates, ResMed (RMD) Q2 Earnings: A Look at Key Metrics (Zacks)
05:20PM	ResMed (RMD) Tops Q2 Earnings and Revenue Estimates (Zacks)
04:48PM	ResMed, In A Buy Zone, Whipsaws Despite Strong Profit Beat (Investor's Business Daily)

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Farrell Michael J.	Chief Executive Officer	Jul 07 '25	Option Exercise	101.64	8,009	814,035	463,512	Jul 09 08:37 AM
Farrell Michael J.	Chief Executive Officer	Jul 07 '25	Sale	256.72	8,009	2,056,076	455,503	Jul 09 08:37 AM
Farrell Michael J.	Officer	Jul 07 '25	Proposed Sale	256.72	8,009	2,056,076		Jul 07 05:21 PM
FARRELL PETER C	Director	Jul 02 '25	Sale	255.49	945	241,438	68,273	Jul 03 12:01 PM
Sandercock Brett	Chief Financial Officer	Jul 01 '25	Option Exercise	101.64	2,883	293,028	88,166	Jul 02 05:53 PM
Sandercock Brett	Chief Financial Officer	Jul 01 '25	Sale	256.99	3,883	997,892	84,283	Jul 02 05:53 PM
FARRELL PETER C	Director	Jul 02 '25	Proposed Sale	264.55	945	250,000		Jul 02 04:15 PM
Rider Michael J	Global General Counsel	Jul 01 '25	Sale	256.99	66	16,961	8,536	Jul 02 03:57 PM
Rider Michael J	Officer	Jul 01 '25	Proposed Sale	256.99	66	16,961		Jul 01 12:40 PM
Sandercock Brett	Officer	Jul 01 '25	Proposed Sale	256.99	3,883	997,892		Jul 01 10:35 AM
Farrell Michael J.	Chief Executive Officer	Jun 09 '25	Option Exercise	101.64	8,009	814,035	463,512	Jun 10 06:35 PM
Farrell Michael J.	Chief Executive Officer	Jun 09 '25	Sale	251.21	8,009	2,011,910	455,503	Jun 10 06:35 PM
Farrell Michael J.	Officer	Jun 09 '25	Proposed Sale	252.00	8,009	2,018,268		Jun 09 10:26 AM
FARRELL PETER C	Director	Jun 04 '25	Sale	247.32	2,000	494,640	69,218	Jun 06 03:22 PM
FARRELL PETER C	Director	Jun 04 '25	Proposed Sale	250.00	2,000	500,000		Jun 04 07:19 PM
Sandercock Brett	Chief Financial Officer	Jun 02 '25	Sale	243.78	1,000	243,780	85,283	Jun 03 05:59 PM
Rider Michael J	Global General Counsel	Jun 02 '25	Sale	243.78	41	9,995	8,870	Jun 03 01:13 PM
Rider Michael J	Officer	Jun 02 '25	Proposed Sale	243.78	41	9,995		Jun 02 01:42 PM
Sandercock Brett	Officer	Jun 02 '25	Proposed Sale	243.78	1,000	243,780		Jun 02 09:58 AM
Sandercock Brett	Chief Financial Officer	May 22 '25	Sale	244.59	3,644	891,286	86,283	May 27 10:24 AM
Sandercock Brett	Officer	May 22 '25	Proposed Sale	244.59	3,644	891,286		May 22 10:25 AM
De Witte Jan	Director	May 20 '25	Sale	243.47	2,000	486,940	5,806	May 22 10:05 AM
De Witte Jan	Director	May 20 '25	Proposed Sale	243.47	2,000	486,940		May 20 11:25 AM
Farrell Michael J.	Chief Executive Officer	May 07 '25	Option Exercise	101.64	8,009	814,035	463,512	May 09 11:01 AM
Farrell Michael J.	Chief Executive Officer	May 07 '25	Sale	243.23	8,009	1,948,003	455,503	May 09 11:01 AM
FARRELL PETER C	Director	May 07 '25	Sale	242.25	2,000	484,500	71,218	May 08 05:38 PM
FARRELL PETER C	Director	May 07 '25	Proposed Sale	250.00	2,000	500,000		May 07 08:12 PM
Farrell Michael J.	Officer	May 07 '25	Proposed Sale	243.23	8,009	1,948,003		May 07 04:14 PM
Sandercock Brett	Chief Financial Officer	Apr 08 '25	Sale	215.58	1,000	215,580	89,864	Apr 10 06:14 PM
Farrell Michael J.	Chief Executive Officer	Apr 07 '25	Option Exercise	101.64	8,009	814,035	463,482	Apr 09 10:52 AM
Farrell Michael J.	Chief Executive Officer	Apr 07 '25	Sale	209.85	8,009	1,680,699	455,472	Apr 09 10:52 AM
Sandercock Brett	Officer	Apr 08 '25	Proposed Sale	215.58	1,000	215,580		Apr 08 09:43 AM
Farrell Michael J.	Officer	Apr 07 '25	Proposed Sale	209.85	8,009	1,680,699		Apr 07 04:15 PM
FARRELL PETER C	Director	Apr 02 '25	Sale	219.74	2,000	439,480	73,218	Apr 04 12:47 PM
Rider Michael J	Global General Counsel	Apr 01 '25	Sale	222.86	64	14,263	8,846	Apr 03 12:59 PM
FARRELL PETER C	Director	Apr 02 '25	Proposed Sale	222.30	2,000	444,600		Apr 02 05:00 PM
Rider Michael J	Officer	Apr 01 '25	Proposed Sale	222.86	64	14,263		Apr 01 11:08 AM
Sandercock Brett	Chief Financial Officer	Mar 10 '25	Sale	230.36	1,000	230,360	90,864	Mar 11 09:56 PM
Ghoshal Kaushik	Chief Commercial Officer, SaaS	Mar 10 '25	Option Exercise	186.53	9,745	1,817,753	19,470	Mar 11 04:19 PM
Ghoshal Kaushik	Chief Commercial Officer, SaaS	Mar 10 '25	Sale	239.31	9,745	2,332,096	9,725	Mar 11 04:19 PM
Farrell Michael J.	Chief Executive Officer	Mar 07 '25	Option Exercise	101.64	8,009	814,035	463,481	Mar 11 11:04 AM
Farrell Michael J.	Chief Executive Officer	Mar 07 '25	Sale	229.20	8,009	1,835,692	455,472	Mar 11 11:04 AM
Ghoshal Kaushik	Officer	Mar 10 '25	Proposed Sale	239.31	9,745	2,332,097		Mar 10 04:42 PM
Sandercock Brett	Officer	Mar 10 '25	Proposed Sale	230.36	1,000	230,360		Mar 10 09:58 AM
Farrell Michael J.	Officer	Mar 07 '25	Proposed Sale	224.43	8,009	1,797,460		Mar 07 12:12 PM
FARRELL PETER C	Director	Mar 05 '25	Sale	227.71	2,000	455,420	75,218	Mar 06 05:40 PM
FARRELL PETER C	Director	Mar 05 '25	Proposed Sale	250.00	2,000	500,000		Mar 05 07:20 PM
Ghoshal Kaushik	Chief Commercial Officer, SaaS	Mar 03 '25	Option Exercise	182.90	9,113	1,666,780	18,838	Mar 04 05:25 PM
Ghoshal Kaushik	Chief Commercial Officer, SaaS	Mar 03 '25	Sale	235.40	9,113	2,145,186	9,725	Mar 04 05:25 PM
Rider Michael J	Global General Counsel	Mar 03 '25	Sale	234.10	64	14,982	8,910	Mar 04 04:51 PM
Ghoshal Kaushik	Officer	Mar 03 '25	Proposed Sale	235.42	9,113	2,145,408		Mar 03 04:40 PM
Rider Michael J	Officer	Mar 03 '25	Proposed Sale	234.10	64	14,982		Mar 03 10:27 AM
Sandercock Brett	Chief Financial Officer	Feb 10 '25	Sale	238.98	1,000	238,980	91,864	Feb 11 12:55 PM
Farrell Michael J.	Chief Executive Officer	Feb 07 '25	Option Exercise	101.64	8,009	814,035	463,481	Feb 11 12:54 PM
Farrell Michael J.	Chief Executive Officer	Feb 07 '25	Sale	236.77	8,009	1,896,307	455,472	Feb 11 12:54 PM
Sandercock Brett	Officer	Feb 10 '25	Proposed Sale	238.98	1,000	238,980		Feb 10 11:31 AM
Farrell Michael J.	Officer	Feb 07 '25	Proposed Sale	236.77	8,009	1,896,307		Feb 07 04:28 PM
FARRELL PETER C	Director	Feb 05 '25	Proposed Sale	250.00	2,000	500,000		Feb 05 06:57 PM
FARRELL PETER C	Director	Feb 05 '25	Sale	242.11	2,000	484,220	77,218	Feb 05 04:49 PM
Rider Michael J	Global General Counsel	Feb 03 '25	Sale	242.42	64	15,515	8,974	Feb 04 12:18 PM
Rider Michael J	Officer	Feb 03 '25	Proposed Sale	242.42	64	15,515		Feb 03 11:12 AM
Sandercock Brett	Chief Financial Officer	Jan 08 '25	Sale	234.04	1,000	234,040	92,864	Jan 10 04:52 PM
Sandercock Brett	Officer	Jan 08 '25	Proposed Sale	234.04	1,000	234,040		Jan 08 10:32 AM
FARRELL PETER C	Director	Jan 02 '25	Sale	230.99	2,000	461,980	79,218	Jan 03 04:57 PM
Rider Michael J	Global General Counsel	Jan 02 '25	Sale	230.99	75	17,324	9,038	Jan 03 04:52 PM
FARRELL PETER C	Director	Jan 02 '25	Proposed Sale	250.00	2,000	500,000		Jan 02 06:06 PM
Rider Michael J	Officer	Jan 02 '25	Proposed Sale	230.99	75	17,324		Jan 02 11:11 AM
Sandercock Brett	Chief Financial Officer	Dec 09 '24	Sale	244.23	1,000	244,230	93,864	Dec 11 01:17 PM
Sandercock Brett	Officer	Dec 09 '24	Proposed Sale	244.23	1,000	244,230		Dec 09 11:12 AM
FARRELL PETER C	Director	Dec 04 '24	Sale	245.65	2,000	491,300	81,218	Dec 05 06:44 PM
FARRELL PETER C	Director	Dec 04 '24	Proposed Sale	250.00	2,000	500,000		Dec 04 07:57 PM
Rider Michael J	Global General Counsel	Dec 02 '24	Sale	248.91	74	18,419	9,113	Dec 02 06:02 PM
Rider Michael J	Officer	Dec 02 '24	Proposed Sale	248.91	74	18,419		Dec 02 11:11 AM
Farrell Michael J.	Director	Nov 27 '24	Proposed Sale	250.00	2,000	500,000		Nov 27 06:17 PM
Farrell Michael J.	Chief Executive Officer	Nov 27 '24	Sale	249.66	2,000	499,330	0	Nov 27 03:19 PM
Leong Justin	Chief Product Officer	Nov 22 '24	Sale	243.09	6,160	1,497,416	21,718	Nov 25 11:14 AM
Leong Justin	Officer	Nov 22 '24	Proposed Sale	243.09	6,160	1,497,418		Nov 22 04:37 PM
De Witte Jan	Director	Nov 12 '24	Sale	248.81	796	198,053	6,723	Nov 14 11:49 AM
Farrell Michael J.	Chief Executive Officer	Nov 07 '24	Option Exercise	84.98	14,683	1,247,761	478,937	Nov 12 05:37 PM
Farrell Michael J.	Chief Executive Officer	Nov 07 '24	Sale	246.26	14,683	3,615,821	464,254	Nov 12 05:37 PM
Sandercock Brett	Chief Financial Officer	Nov 08 '24	Sale	249.00	1,000	249,000	94,864	Nov 12 04:33 PM
De Witte Jan	Director	Nov 12 '24	Proposed Sale	248.81	796	198,053		Nov 12 11:54 AM
FARRELL PETER C	Director	Nov 06 '24	Sale	248.74	2,000	497,480	83,204	Nov 08 01:15 PM
Sandercock Brett	Officer	Nov 08 '24	Proposed Sale	249.00	1,000	249,000		Nov 08 10:51 AM
Farrell Michael J.	Officer	Nov 07 '24	Proposed Sale	246.26	14,683	3,615,821		Nov 07 04:30 PM
FARRELL PETER C	Director	Nov 06 '24	Proposed Sale	248.74	2,000	497,480		Nov 06 06:22 PM
Rider Michael J	Global General Counsel	Nov 01 '24	Sale	242.00	69	16,698	10,443	Nov 05 12:20 PM
Rider Michael J	Officer	Nov 01 '24	Proposed Sale	242.00	69	16,698		Nov 01 10:27 AM
Ghoshal Kaushik	Chief Commercial Officer, SaaS	Oct 11 '24	Option Exercise	101.64	4,260	432,986	26,048	Oct 15 10:06 AM
Ghoshal Kaushik	Chief Commercial Officer, SaaS	Oct 11 '24	Sale	238.48	4,260	1,015,925	21,788	Oct 15 10:06 AM
Ghoshal Kaushik	Officer	Oct 11 '24	Proposed Sale	238.48	4,260	1,015,925		Oct 11 09:51 AM
Sandercock Brett	Chief Financial Officer	Oct 08 '24	Sale	233.47	1,000	233,470	95,812	Oct 09 04:38 PM
Farrell Michael J.	Chief Executive Officer	Oct 07 '24	Option Exercise	84.98	14,683	1,247,761	478,852	Oct 09 01:44 PM
Farrell Michael J.	Chief Executive Officer	Oct 07 '24	Sale	231.91	14,683	3,405,206	464,169	Oct 09 01:44 PM
Sandercock Brett	Officer	Oct 08 '24	Proposed Sale	233.47	1,000	233,470		Oct 08 11:08 AM
Farrell Michael J.	Officer	Oct 07 '24	Proposed Sale	231.91	14,683	3,405,206		Oct 07 04:40 PM
FARRELL PETER C	Director	Oct 02 '24	Sale	237.20	2,000	474,400	85,204	Oct 02 04:20 PM
FARRELL PETER C	Director	Oct 02 '24	Proposed Sale	238.75	2,000	477,500		Oct 02 02:46 PM
Ghoshal Kaushik	Chief Commercial Officer, SaaS	Sep 12 '24	Option Exercise	101.64	5,000	508,200	26,788	Sep 13 02:54 PM
Ghoshal Kaushik	Chief Commercial Officer, SaaS	Sep 12 '24	Sale	252.56	5,000	1,262,800	21,788	Sep 13 02:54 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RMD

Resmed Inc

Upgrade your FINVIZ experience